Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-24-088969
Filing Date
2024-10-18
Accepted
2024-10-18 16:31:39
Documents
57
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN PRIVATE ISSUER ea0216876-6k_nlspharma.htm   iXBRL 6-K 17279
2 UNAUDITED INTERIM CONDENSED FINANCIAL STATEMENTS OF NLS PHARMACEUTICS AS OF JUNE ea021687601ex99-1_nlspharma.htm   iXBRL EX-99.1 380964
3 MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERA ea021687601ex99-2_nlspharma.htm EX-99.2 140042
  Complete submission text file 0001213900-24-088969.txt   3782141

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE nlsp-20240630.xsd EX-101.SCH 38866
5 XBRL CALCULATION FILE nlsp-20240630_cal.xml EX-101.CAL 29803
6 XBRL DEFINITION FILE nlsp-20240630_def.xml EX-101.DEF 192943
7 XBRL LABEL FILE nlsp-20240630_lab.xml EX-101.LAB 360870
8 XBRL PRESENTATION FILE nlsp-20240630_pre.xml EX-101.PRE 207226
60 EXTRACTED XBRL INSTANCE DOCUMENT ea0216876-6k_nlspharma_htm.xml XML 361149
Mailing Address THE CIRCLE 6 8058 ZURICH V8 CH-6370
Business Address THE CIRCLE 6 8058 ZURICH V8 CH-6370 41-41-618-80-00
NLS Pharmaceutics Ltd. (Filer) CIK: 0001783036 (see all company filings)

EIN.: 000000000 | State of Incorp.: V8 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-39957 | Film No.: 241381091
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)